Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure.

AIDS (London, England) - 14 Jan 2012

Li Jonathan Z, Paredes Roger, Ribaudo Heather J, Svarovskaia Evguenia S, Kozal Michael J, Hullsiek Katherine H, Miller Michael D, Bangsberg David R, Kuritzkes Daniel R

Abstract excerpt

OBJECTIVES: To evaluate the risk of virologic failure conferred by suboptimal adherence to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and minority NNRTI resistance mutations. DESIGN: Pooled analysis of the risk of virologic failure conferred by minority NNRTI resistance mutations and NNRTI adherence from three studies of treatment-naïve individuals initiating an NNRTI-based regimen. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to CD4 Lymphocyte Count

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Counseling

Share to Drug Resistance, Viral

Share to HIV Infections

Share to Reverse Transcriptase Inhibitors

Share to Viral Load

Source

Open in PubMed Open full text

Identifiers

PMID: 22179227
DOI: 10.1097/QAD.0b013e32834e9d7d
PMCID: PMC3437231

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure.PMID 22179227Read ↗

Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.Semantic proximity Read ↗

Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.Semantic proximity Read ↗

Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy.Semantic proximity Read ↗

Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.Semantic proximity Read ↗

Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible?Semantic proximity Read ↗

Prevalence of Drug-Resistant Minority Variants in Untreated HIV-1-Infected Individuals With and Those Without Transmitted Drug Resistance Detected by Sanger Sequencing.Semantic proximity Read ↗

Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.Semantic proximity Read ↗

Clinical implications of HIV-1 minority variants.Semantic proximity Read ↗

Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.Semantic proximity Read ↗

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen.Semantic proximity Read ↗

Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection.Semantic proximity Read ↗

Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.